See What HealthDay Can Do For You
Contact Us

Baseline Inflammation Tied to Lower PCa Risk on Repeat Biopsy

Even after adjustment, acute, chronic inflammation linked to lower PCa risk at two-year repeat biopsy

Baseline Inflammation Tied to Lower PCa Risk on Repeat Biopsy

TUESDAY, Dec. 10, 2013 (HealthDay News) -- Among men with a negative biopsy for prostate cancer (PCa), acute and chronic inflammation at baseline correlate with a lower PCa risk at repeat two-year biopsy, according to a study published online Dec. 9 in Cancer.

Daniel M. Moreira, M.D., from The Arthur Smith Institute for Urology in New Hyde Park, N.Y., and colleagues conducted a retrospective analysis involving 6,238 men aged 50 to 75 years with prostate-specific antigen levels between 2.5 and 10.0 ng/mL and a prior negative biopsy. The authors sought to examine whether baseline acute and chronic prostate inflammation was associated with the risk of subsequent PCa detection. The association between inflammation in baseline prostate biopsies and positive two- and four-year repeat biopsies was assessed, with adjustment for baseline covariates.

The researchers found that acute inflammation, chronic inflammation, and both were detected in 1, 63, and 14 percent of baseline biopsies, respectively. The prevalence of PCa was 14 percent at the two-year biopsy. Both acute and chronic inflammation correlated significantly with a lower risk of PCa at the two-year biopsy (acute inflammation: odds ratio, 0.65 in univariate analysis and 0.75 on multivariate analysis; chronic inflammation: odds ratio, 0.61 on univariate analysis and 0.65 in multivariate analysis). Only acute inflammation was associated with lower PCa risk at the time of the four-year biopsy.

"Baseline acute and chronic inflammation were both found to be independently associated with a lower PCa risk," the authors write. "From a clinical standpoint, inflammation in negative biopsies for PCa may lower the risk of subsequent PCa detection."

One author is employed by GlaxoSmithKline; several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Physician's Briefing